Technical Analysis for STML - Stemline Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 7.03 0.00% 0.00
STML closed unchanged on Friday, January 17, 2020, on 1.57 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical STML trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Volume Surge Other 0.00%
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Biopharmaceutical Cancer Biology Stem Cells Tumor Platform Technology Refractory Acute Myeloid Leukemia Carcinogenesis Cancer Stem Cell Cancer Stem Cells

Is STML a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 18.22
52 Week Low 6.01
Average Volume 760,391
200-Day Moving Average 12.27
50-Day Moving Average 9.97
20-Day Moving Average 9.76
10-Day Moving Average 8.87
Average True Range 0.69
ADX 26.3
+DI 13.09
-DI 42.17
Chandelier Exit (Long, 3 ATRs ) 9.32
Chandelier Exit (Short, 3 ATRs ) 8.08
Upper Bollinger Band 12.74
Lower Bollinger Band 6.78
Percent B (%b) 0.04
BandWidth 61.01
MACD Line -0.78
MACD Signal Line -0.34
MACD Histogram -0.4391
Fundamentals Value
Market Cap 164.89 Million
Num Shares 23.5 Million
EPS -2.47
Price-to-Earnings (P/E) Ratio -2.85
Price-to-Sales 202.21
Price-to-Book 3.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.71
Resistance 3 (R3) 7.75 7.57 7.59
Resistance 2 (R2) 7.57 7.40 7.55 7.55
Resistance 1 (R1) 7.30 7.29 7.21 7.26 7.52
Pivot Point 7.12 7.12 7.08 7.10 7.12
Support 1 (S1) 6.85 6.95 6.76 6.81 6.54
Support 2 (S2) 6.67 6.84 6.65 6.51
Support 3 (S3) 6.40 6.67 6.47
Support 4 (S4) 6.36